Preclinical Development Handbook 2007
DOI: 10.1002/9780470249031.ch31
|View full text |Cite
|
Sign up to set email alerts
|

Experimental Design Considerations in Pharmacokinetic Studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 2 publications
(5 reference statements)
0
1
0
Order By: Relevance
“…While some PFAS rapidly transform to one of these eleven PFAS in vivo, [ 45 ] there are many thousands more for which there are no data available [ 12 ]. This is, in part, because in vivo experiments are resource intensive [ 46 , 47 ]. Additionally, higher throughput toxicokinetic methods perform poorly for some PFAS due to a lack of data characterizing transporters [ 23 ].…”
Section: Introductionmentioning
confidence: 99%
“…While some PFAS rapidly transform to one of these eleven PFAS in vivo, [ 45 ] there are many thousands more for which there are no data available [ 12 ]. This is, in part, because in vivo experiments are resource intensive [ 46 , 47 ]. Additionally, higher throughput toxicokinetic methods perform poorly for some PFAS due to a lack of data characterizing transporters [ 23 ].…”
Section: Introductionmentioning
confidence: 99%